A gene change called EGFR and survival in glioblastoma
Original title: Epidermal Growth Factor Receptor (EGFR) Amplification and Survival in Patients With Glioblastoma: A Systematic Review and Meta-Analysis.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This looks back at records from past patients and does not test any treatment.
The short version
Tumors with many extra copies of the EGFR gene were linked to shorter survival.
What was studied. Researchers pooled the results of nine past studies. Those studies covered 1,766 people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. They looked at EGFR gene copies along with two other tumor markers, IDH and MGMT.
What they found. Low or moderate amounts of extra EGFR copies were not linked to how long people lived. High amounts were linked to a higher risk of dying. The link to survival also shifted depending on the MGMT and IDH markers. Tumors with no extra EGFR and an IDH change did the best.
What this means, and what it doesn't
What it could mean: Tumor gene tests may help a care team judge how a tumor is likely to behave. That can help with planning and with talks about what to expect. It does not change the treatment you can get today.
What it doesn't mean: This is not a new treatment, and it is not a cure. The team only pooled numbers from studies that were already done. That kind of study can show a link, but it cannot prove cause. One gene test does not decide how any single person will do.
Source: PubMed, July 25, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.